Mesoblast Limited Sponsored ADR Stock

$10.18

5.04%

Nasdaq, Apr 21, 09:16 pm CET

ISIN

US5907171046

Symbol

MESO

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Mesoblast Limited Sponsored ADR Stock price

$10.72

-2.98 21.75% 5Y

Nasdaq, Closing price Thu, Apr 17 2025

+0.41 3.98%

ISIN

US5907171046

Symbol

MESO

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$1.37b
Enterprise Value	$1.46b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	257.27
P/S ratio (TTM) P/S ratio	241.71
P/B ratio (TTM) P/B ratio	2.68
Revenue (TTM) Revenue	$5.66m
EBIT (operating result TTM) EBIT	$-51.63m
Free Cash Flow (TTM) Free Cash Flow	$-49.73m
EPS (TTM) EPS	$-0.93
P/E forward	negative
P/S forward	75.29
EV/Sales forward	80.13
Short interest	2.47%

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Get Started for Free Today

Mesoblast Limited Sponsored ADR Stock Analysis

Unlock Scores for Free

??

6 Analysts have issued a Mesoblast Limited Sponsored ADR forecast:

6x Buy

100%

More details on Analyst Estimates Including Price Targets

6 Analysts have issued a Mesoblast Limited Sponsored ADR forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Mesoblast Limited Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

TTM Annually

Dec '24		+/- %
Revenue	5.66 5.66	27% 27% 100%
- Direct Costs	-3.73 -3.73	113% 113% -66%
Gross Profit	9.38 9.38	150% 150% 166%
- Selling and Administrative Expenses	23 23	8% 8% 414%
- Research and Development Expense	33 33	22% 22% 588%
EBITDA	-47 -47	- -836%
- Depreciation and Amortization	4.30 4.30	- 76%
EBIT (Operating Income) EBIT	-52 -52	29% 29% -912%
Net Profit	-103 -103	26% 26% -1,822%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Mesoblast Limited Sponsored ADR Stock News

Neutral

GlobeNewsWire

●

5 days ago

Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives

NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has continued to expand coverage for Ryoncil® (remestemcel-L), the first mesenchymal stromal cell (MSC) therapy approved by U.S. Food and Drug Administration (FDA) for any indication, to 104 million US lives insured by g...

Neutral

GlobeNewsWire

●

18 days ago

Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin' and Not Subject to U.S. Tariffs

NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the status of its products in relation to the U.S. Government's announcement on tariffs for imported products. Mesoblast believes that its allogeneic cellular products, including Ryoncil® and Revascor®, will not be s...

Neutral

GlobeNewsWire

●

19 days ago

Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure

NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its plans to meet with the United States Food and Drug Administration (FDA) to discuss the accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failur...

More Mesoblast Limited Sponsored ADR News

Company Profile

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.

Head office	Australia
CEO	Silviu Itescu
Employees	73
Founded	2004
Website	www.mesoblast.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now